Business Context and Reporting Period
Company: MUSTANG BIO, INC. (MBIO)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Mustang Bio is a clinical-stage biopharmaceutical company focused on CAR T therapies for hematologic malignancies, autoimmune diseases, and solid tumors. The company operates as a majority-controlled subsidiary of Fortress Biotech, Inc. It has no approved products and generates no product revenue.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(15.8) million | $(51.6) million |
| Operating Expenses | $16.2 million | $49.3 million |
| Cash and Cash Equivalents (Dec 31, 2024) | $6.8 million | $6.2 million |
| Accumulated Deficit | $(396.7) million | $(381.0) million |
| Stockholders' Equity | $(3.9) million | $0.1 million |
Note: The company reported a stockholders' deficit of $3.7 million as of December 31, 2024, in the Risk Factors section, while the Balance Sheet shows $(3.9) million. The Balance Sheet figure is used for the table above.
Material Changes vs. Prior Period
- Significant Cost Reduction: Total operating expenses decreased by 67% (from $49.3 million to $16.2 million), driven by an 81% workforce reduction in April 2024 and the termination of several clinical programs.
- Asset Impairment: The company recorded a $3.7 million asset impairment charge in 2024 related to leasehold improvements and equipment held for sale, compared to none in 2023.
- Program Termination: Development of MB-106 for hematologic malignancies was paused to prioritize autoimmune disease trials. Licenses with St. Jude, Leiden University Medical Centre, and Mayo Clinic were terminated, resulting in the forgiveness of approximately $0.9 million in payables.
- Manufacturing Facility: The company sold its Worcester, MA manufacturing facility assets to uBriGene in 2023 but was forced to repurchase them in June 2024 following a CFIUS National Security Agreement. The lease for the facility was subsequently terminated in early 2025.
Guidance, Outlook, and Risks
Going Concern
The filing explicitly states there is substantial doubt regarding the company's ability to continue as a going concern for one year following the issuance of the financial statements. The company requires additional financing to fund operations.
Outlook and Pipeline
- MB-106 (CD20 CAR T): Pivotal Phase 2 trial for Waldenstrom macroglobulinemia (WM) is not expected to initiate in 2025 due to limited resources. Development is currently focused on autoimmune diseases, with a Phase 1 trial planned for Q4 2025.
- MB-109 (MB-101 + MB-108): A combination therapy for glioblastoma. The company is exploring an investigator-sponsored trial at City of Hope, potentially initiating in Q4 2025.
- Regulatory Milestones: MB-108 received Orphan Drug Designation in November 2024. MB-106 received Regenerative Medicine Advanced Therapy (RMAT) designation in March 2024.
Recent Financing and Listing Status
- Capital Raises: The company raised approximately $11.2 million in net proceeds during 2024 through various equity offerings and warrant exercises. A subsequent public offering in February 2025 raised approximately $6.9 million.
- Nasdaq Compliance: The company faced delisting risks due to minimum bid price and stockholders' equity deficiencies. It regained compliance in February 2025 following a 1-for-50 reverse stock split and the February 2025 equity offering.
Investor Verification Checklist
- Liquidity Runway: Verify if the $6.9 million raised in February 2025, combined with existing cash, is sufficient to fund operations through 2025 as management claims, given the substantial doubt on going concern.
- Manufacturing Strategy: Confirm the status of the repurchased manufacturing assets and the timeline for the new investigator-sponsored trials at City of Hope and Fred Hutch, as the company no longer operates its own facility.
- Fortress Biotech Relationship: Review the Founders Agreement terms, specifically the 2.5% equity fee on financings and the annual stock dividend, which causes dilution to common shareholders.
- Program Prioritization: Assess the risk of further delays or termination of the MB-106 WM program if additional capital is not secured.
- Nasdaq Monitoring: Monitor the one-year mandatory monitoring period by the Nasdaq Hearings Panel following the regained compliance.